1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Bavarian Nordic A/S
  6. News
  7. Summary
    BAVA   DK0015998017

BAVARIAN NORDIC A/S

(BAVA)
  Report
Real-time Estimate Cboe Europe  -  09:43 2022-08-08 am EDT
367.75 DKK   -6.73%
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
08/04How worried should we be about the monkeypox health emergency?
RE
08/03Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Monkeypox Vaccine in 2023
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Britain offers smallpox shot as monkeypox cases spread in Europe

05/19/2022 | 08:37am EDT
FILE PHOTO: A section of skin tissue, harvested from a lesion on the skin of a monkey, that had been infected with monkeypox virus

LONDON (Reuters) - A smattering of monkeypox cases in Britain has prompted authorities to offer a smallpox vaccine to some healthcare workers and others who may have been exposed, as a handful more cases were confirmed in parts of Europe.

Monkeypox is a usually mild viral illness, characterised by symptoms of fever as well as a distinctive bumpy rash.

There are two main strains: the Congo strain, which is more severe - with up to 10% mortality - and the West African strain, which has a fatality rate of about 1%.

First identified in monkeys, the viral disease typically spreads through close contact and largely occurs in west and central Africa. It has rarely spread elsewhere, so this fresh spate of cases outside the continent has triggered concern.

In the United Kingdom, nine cases of the West African strain have been reported so far.

There isn't a specific vaccine for monkeypox, but a smallpox vaccine does offer some protection, a UK Health Security Agency (UKHSA) spokesperson said.

Data shows that vaccines that were used to eradicate smallpox are up to 85% effective against monkeypox, according to the World Health Organisation.

"Those who have required the vaccine have been offered it," the UKHSA spokesperson added, without disclosing specifics on how many people have been vaccinated so far.

Some countries have large stockpiles of the smallpox vaccine as part of pandemic preparedness, including the United States.

Copenhagen-based drugmaker Bavarian Nordic on Thursday said it had secured a contract with an undisclosed European country to supply its smallpox vaccine, Imvanex, in response to the monkeypox outbreak.

CASES

The first European case was confirmed on May 7 in an individual who returned to England from Nigeria, where monkeypox is endemic.

Since then, Portugal has logged 14 cases, and Spain has confirmed seven cases. The United States and Sweden have also reported one case each. Italian authorities have confirmed one case, and suspect two more.

Several monkeypox outbreaks in Africa have been contained during the COVID pandemic while the world's attention was elsewhere, Africa's top public health agency said on Thursday.

"We are however concerned at the multiple countries outside, especially in Europe, that are seeing these outbreaks of monkeypox," the acting director of the Africa Centres for Disease Control and Prevention, Ahmed Ogwell Ouma, said.

"It would be very useful for knowledge to be shared regarding what the source of these outbreaks actually are," he said.

Meanwhile, in Britain, the UKHSA has highlighted that the recent cases in the country were predominantly among men who self-identified as gay, bisexual or men who have sex with men.

This unusual spike in cases outside of Africa could suggest a novel means of spread or a change in the virus, said Anne Rimoin, an epidemiology professor at UCLA in California. "But this is all to be determined".

"This isn't going to cause a nationwide epidemic like COVID did," cautioned Jimmy Whitworth, professor of international public health at the London School of Hygiene and Tropical Medicine.

"But it's a serious outbreak of a serious disease - and we should take it seriously."

(Reporting by Jennifer Rigby and Natalie Grover in London; Twitter @NatalieGrover; additional reporting by Anna Ringstrom in Stockholm and Agnieszka Flak in Milan; Editing by Elaine Hardcastle)

By Jennifer Rigby


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BAVARIAN NORDIC A/S -6.64% 367.7 Delayed Quote.46.69%
DOW JONES AFRICA TITANS 50 INDEX 2.14% 463.85 Real-time Quote.-15.39%
S&P AFRICA 40 INDEX 2.12% 152.22 Real-time Quote.-14.84%
All news about BAVARIAN NORDIC A/S
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
08/04How worried should we be about the monkeypox health emergency?
RE
08/03Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Mon..
GL
08/03Bavarian Nordic Enters Additional Contract with APAC Country for Supply of Smallpox/Mon..
GL
08/03Bavarian Nordic A/S Enters Additional Contract with APAC Country for Supply of Smallpox..
CI
08/03Bavarian Nordic A/S Enters Additional Contract with APAC Country for Supply of Smallpox..
CI
07/31NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/28EUROPEAN MIDDAY BRIEFING : Mixed Earnings Drag on -2-
DJ
07/27U.S. to release 786K monkeypox vaccine doses amid shortage, disease spread
AQ
07/27US signs off on 800,000 more doses of monkeypox vaccine
AQ
More news
Analyst Recommendations on BAVARIAN NORDIC A/S
More recommendations
Financials
Sales 2022 2 883 M 393 M 393 M
Net income 2022 -590 M -80,5 M -80,5 M
Net cash 2022 2 092 M 285 M 285 M
P/E ratio 2022 -47,1x
Yield 2022 -
Capitalization 27 732 M 3 784 M 3 784 M
EV / Sales 2022 8,89x
EV / Sales 2023 3,79x
Nbr of Employees 830
Free-Float 99,8%
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 394,30 DKK
Average target price 400,14 DKK
Spread / Average Target 1,48%
EPS Revisions
Managers and Directors
Paul Chaplin President & Chief Executive Officer
Henrik Neilsen Juuel Chief Financial Officer & Executive Vice President
Gerardus Wilhelmus van Odijk Chairman
Laurence de Moerlooze Chief Medical Officer & Executive Vice President
Russell Thirsk Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
BAVARIAN NORDIC A/S46.69%3 784
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-16.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068